 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Jul 22, 2021 |
| Title |
Anti-CD4 treatment-induced IL18Rαhi CD8+ T cells show highly effector profile |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Anti-CD4 monoclonal antibody, a prominent immunomodulatory agent, enriches IL18Rαhi CD8+ T cells that elicit robust anti-tumor immunity in B16F10 melanoma. To investigate gene-expression profile of IL18Rαhi subset, we conducted transcriptome analysis.
|
| |
|
| Overall design |
The model of mouse melanoma (B16F10) was used to study IL18Rαhi CD8+ T cells. We designed a regimen that utilizes cyclophosphamide treatment, adoptive transfer of tumor-specific T cells, and anti-CD4 treatment, a combination that synergistically increases the efficacy of adoptive T cell therapy. Three days after the B16F10 challenge, C57BL/6 mice sequentially received cyclophosphamide, ex vivo-primed Pmel-1 cells (melanoma-specific TCR-transgenic CD8+ T cells), and IL-2. A transient treatment (on day 10, 17, and 24) of anti-CD4 started seven days after cyclophosphamide treatment. Twenty-five days after the tumor challenge, cells from lymphoid tissues of the mice were magnetically isolated based on the IL18Rα expression and subjected to transcriptome analysis.
|
| |
|
| Contributor(s) |
Han C, Kim S |
| Citation(s) |
34493727 |
| |
| Submission date |
Jul 20, 2021 |
| Last update date |
Sep 29, 2021 |
| Contact name |
Chungyong Han |
| Organization name |
National Cancer Center
|
| Street address |
323 Ilsan-ro, Ilsandong-gu
|
| City |
Goyang-si |
| State/province |
Gyeonggi-do |
| ZIP/Postal code |
10408 |
| Country |
South Korea |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (8)
|
|
| Relations |
| BioProject |
PRJNA748267 |
| SRA |
SRP329082 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE180439_Gene_expression_RNA-seq_IL18Ra.txt.gz |
1.3 Mb |
(ftp)(http) |
TXT |
SRA Run Selector |
| Raw data are available in SRA |
| Processed data are available on Series record |
|
|
|
|
 |
Less...
More...